AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, a Dividend King, is acquiring Apogee Therapeutics for $10.9 billion to strengthen its drug pipeline and maintain its dividend growth streak. The deal brings late-stage drug candidates like zumilokibart for atopic dermatitis and respiratory drugs, helping AbbVie replace revenue lost from Humira's patent expiration with newer products like Skyrizi and Rinvoq.

07/11/2026, 8:15 PM • The Motley Fool

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

ProShares vs. iShares: Is NOBL or HDV the Better Dividend ETF for Investors?

The article compares two dividend-focused ETFs: iShares Core High Dividend ETF (HDV) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL). HDV offers a lower expense ratio (0.08% vs 0.35%), higher dividend yield (2.90% vs 2.07%), and stronger recent performance (21.5% vs 14.9% over one year) with lower volatility. The author recommends HDV as the better long-term choice due to its superior yield, lower costs, and smoother risk profile, despite both funds delivering similar historical returns.

07/09/2026, 7:34 AM • The Motley Fool

Internationales Beratergremium für Handel und Investitionen in Shandong 2026 tagt in Jinan

Shandong province held its 2026 International Trade and Investment Advisors Roundtable on July 7, bringing together international advisors and representatives from over ten countries. The roundtable focused on AI-driven development, digital transformation, green manufacturing, and business environment improvements. Shandong is developing four strategic industries targeting one trillion yuan each and four emerging sectors targeting 100 billion yuan each, including AI, biomedics, and alternative energy vehicles. International companies presented forward-looking proposals on AI integration, industry transformation, and green development.

07/09/2026, 2:56 AM • GlobeNewswire

Si è tenuta a Jinan la tavola rotonda 2026 dei consulenti internazionali per il commercio e gli investimenti dello Shandong

Shandong province held its 2026 International Trade and Investment Advisors Roundtable in Jinan, bringing together international advisors from over 10 countries to discuss high-level opening, digital transformation, green manufacturing, and business environment improvements. The roundtable highlighted Shandong's 15th Five-Year Plan focusing on emerging pillar industries in high-end equipment, IT services, new energy, and new materials, along with high-potential sectors in AI, biomedicine, and new energy vehicles. International companies presented proposals on AI integration with advanced manufacturing and green development initiatives.

07/09/2026, 2:56 AM • GlobeNewswire

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT's stronger 10-year performance, PJP is recommended as the better buy due to its superior 5-year returns, lower volatility, dividend yield, and more stable risk profile.

07/08/2026, 6:04 PM • The Motley Fool

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.

07/08/2026, 5:03 PM • The Motley Fool

ASDS Opens Registration for Annual Conference in San Diego

The American Society for Dermatologic Surgery (ASDS) has opened registration for its 2026 Annual Meeting scheduled for November 5-8 in San Diego. The conference will feature over 85 educational sessions, hands-on workshops, live surgical demonstrations, and networking opportunities for dermatologic surgeons. ASDS members receive a $1,300 discount on registration, and scholarships up to $750 are available for eligible dermatology residents.

07/08/2026, 1:56 PM • GlobeNewswire

The Dividend ETF Quietly Outperforming the S&P 500

The iShares Core High Dividend ETF (HDV) has gained over 15% year-to-date, outperforming the S&P 500's 9% return. The fund's success is driven by its high-quality dividend stock selection and significant exposure to energy stocks (ExxonMobil, Chevron) and healthcare stocks (AbbVie, Merck), which have all posted strong gains. HDV's focus on financially healthy companies with sustainable competitive advantages has delivered consistent returns over multiple time periods.

07/07/2026, 5:30 AM • The Motley Fool

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

The European Commission has approved TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. The Phase 3 EPCORE® FL-1 trial demonstrated that the fixed-duration combination therapy reduced disease progression or death risk by 79% compared to standard care, with 96% overall response rate and 74% complete response rate, offering a chemotherapy-free treatment option.

07/06/2026, 1:59 PM • GlobeNewswire

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) but carries significantly higher risk (54% maximum drawdown) and costs (0.35% expense ratio), appealing to aggressive investors.

07/05/2026, 9:15 AM • The Motley Fool

Which Is the Better High Dividend ETF, iShares' HDV or Fidelity's FDVV?

iShares' HDV and Fidelity's FDVV both offer 2.80% dividend yields but follow different strategies. HDV focuses on defensive sectors (healthcare, energy) with lower costs (0.08% expense ratio) and lower volatility, making it ideal for conservative investors. FDVV emphasizes tech stocks with higher growth potential but carries higher costs (0.15% expense ratio) and volatility, delivering stronger 5-year returns ($1,883 vs $1,673 on $1,000 invested).

07/04/2026, 5:05 PM • The Motley Fool

Exploring SKYRIZI's Exceptional Growth: Revenue and Market Expansion Analysis

SKYRIZI, AbbVie's IL-23 inhibitor, has achieved blockbuster status with global sales reaching $11.7 billion in 2024 (51% YoY growth). The drug is expanding across multiple indications including psoriasis, psoriatic arthritis, and IBD, with strong gastroenterology uptake and favorable dosing schedules. AbbVie forecasts combined revenues for SKYRIZI and Rinvoq to exceed $31 billion annually by 2027, positioning SKYRIZI as the largest contributor to its $26.7 billion immunology portfolio.

07/03/2026, 7:57 AM • GlobeNewswire

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

AbbVie hit a new 52-week high and is up 40% over the past 12 months, though year-to-date gains are modest at 11%. Despite the elevated stock price, the company trades at less than 18x forward earnings—below the S&P 500 average of 21—making it reasonably valued. The pharmaceutical giant's recent $10.9 billion acquisition of Apogee Therapeutics and strong financial performance support its position as an attractive long-term dividend stock.

06/29/2026, 11:21 AM • The Motley Fool